Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK has more mixed PhIII Relovair data for COPD, but submissions remain on track

This article was originally published in Scrip

Executive Summary

GlaxoSmithKline and its partner Theravance have put forward additional mixed Phase III top-line data for once-daily Relovair, a drug containing fluticasone furoate, an inhaled corticosteroid, and vilanterol, a long-acting beta2 agonist (LABA) - this time in two non-pivotal trials for treatment of chronic obstructive pulmonary disease (COPD).

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC016739

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel